Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

CLEVIPREX

CLEVIDIPINE

Standard Dose
125MG/250ML (0.5MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview CLEVIPREX is listed in Drugs@FDA under application 022156 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient CLEVIDIPINE Form and strength EMULSION;INTRAVENOUS - 125MG/250ML (0.5MG/ML) Sponsor CHIESI Submission history Latest submission status date: 2021-04-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview CLEVIPREX is listed in Drugs@FDA under application 022156 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CLEVIDIPINE Form and strength EMULSION;INTRAVENOUS - 125MG/250ML (0.5MG/ML) Sponsor CHIESI Submission history Latest submission status date: 2021-04-16 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.